

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

GLAXOSMITHKLINE PLC
Form 6-K
April 02, 2008

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending April 02, 2008

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F
or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging Managerial
Responsibility or Connected Persons

I give below details of changes in the directors' interests in the Ordinary
shares and American Depositary Shares (ADSs) of GlaxoSmithKline plc.

On 31 March 2008, the Company's Non-Executive Directors were provisionally
allocated the following awards over Ordinary Shares and ADSs under the share
allocation arrangements for Non-Executive Directors for the period of service

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

from 1 January 2008 to 31 March 2008:

Non Executive Director	Ordinary Shares	American Depository Shares (ADSS)
Sir Christopher Gent	2,694.47	
Prof Sir Roy Anderson	761.48	
Dr Stephanie Burns		321.03
Mr Lawrence Culp		642.07
Sir Crispin Davis	2,343.02	
Sir Deryck Maughan		642.07
Dr Daniel Podolsky		481.55
Sir Ian Prosser	1522.96	
Dr Ronaldo Schmitz	937.21	
Mr Tom de Swaan	761.48	
Sir Robert Wilson	702.91	

The Company and the Non-Executive Directors were informed of these allocations on 1 April 2008.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1) (a).

S M Bicknell
Company Secretary
2 April 2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 02, 2008

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc